Today 2026.10.07 D-End
Today 
|
[OP01] Oral Presentation 1 |
Room A (1F) |
||
|---|---|---|---|
| Date & Time | Sep. 17 (Thu), 09:00-10:00 | ||
| Chair(s) |
Yeon Jung Lim (Chungnam National University College of Medicine, Korea) Seok Lee (Ewha Womans University College of Medicine, Korea) |
||
| Speaker(s) | 09:00-09:10 | Distinct Genetic Architecture and Integrated Risk Stratification in Adult ETP-ALL and Other T-ALL Seonghan Lee (College of Medicine, The Catholic University of Korea, Korea) | |
| 09:10-09:20 | Phase 2 Study Results; Clinical Outcomes of Adults with Ph-Positive ALL Treated with Frontline Ponatinib Plus Hyper-CVAD Followed by RTC-Allo-HCT Incorporating ATG/PTCy with Ponatinib Prophylaxis Jong Hyuk Lee (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:20-09:30 | Inotuzumab Ozogamicin as Salvage Therapy Prior to Second Allogeneic Hematopoietic Cell Transplantation Reduces Relapse without Increasing Non-Relapse Mortality in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Joon Young Hur (University of Ulsan College of Medicine, Korea) | ||
| 09:30-09:40 | TAL1 Activation Mechanisms Stratify Relapse Risk and Identify a High-Risk Subgroup Unresponsive to HSCT in Pediatric T-ALL Senlin Zhang (Children's Hospital of Soochow University, China) | ||
| 09:40-09:50 | Genomic Landscape and Clinical Outcomes of MTAP Rearrangements in Pediatric T-Cell Acute Lymphoblastic Leukemia: A Retrospective Cohort Study Shier Cheng (Children's Hospital of Soochow University, China) | ||
| 09:50-10:00 | Successful Transplant-Sparing Management of EBF1: PDGFRB-Positive Ph-like Acute Lymphoblastic Leukemia Using Imatinib and CD19 CAR-T Therapy with Prolonged TKI Maintenance Hina Nakajima (Chiba University Hospital, Japan) | ||
|
[OP02] Oral Presentation 2 |
Room B (1F) |
||
|---|---|---|---|
| Date & Time | Sep. 17 (Thu), 09:00-10:00 | ||
| Chair(s) |
Jeong A Kim (College of Medicine, The Catholic University of Korea, Korea) Sung Hwa Bae (Daegu Catholic University School of Medicine, Korea) |
||
| Speaker(s) | 09:00-09:10 | Multi-Trajectories of Lipid Profiles and Their Association with Clinical Outcomes in AML Patients Undergoing Allo-HSCT Hongru Chen (Peking University People's Hospital, China) | |
| 09:10-09:20 | High Frequency of Extramedullary Relapse in Very Late Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation Jin-Hee Han (University of Ulsan College of Medicine, Korea) | ||
| 09:20-09:30 | Comparable Post-Transplant Outcomes Following Intensive Chemotherapy versus Hypomethylating Agent plus Venetoclax before First Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Hyunkyung Park (University of Ulsan College of Medicine, Korea) | ||
| 09:30-09:40 | Efficacy and Safety of Venetoclax and Azacitidine Maintenance in Reducing Relapse after Haploidentical HSCT for Pediatric AML: A Retrospective Two-Center Cohort Study He Hongbo (Beijing Children's Hospital, China) | ||
| 09:40-09:50 | Venetoclax plus Hypomethylating Agents for Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation Jiseon Park (University of Ulsan College of Medicine, Korea) | ||
| 09:50-10:00 | HCT-CI Failed to Predict Survival Outcomes in Elderly Patients with AML/MDS Undergoing Haploidentical Transplantation Yuqian Sun (Peking University People's Hospital, China) | ||
|
[OP03] Oral Presentation 3 |
Room C (2F) |
||
|---|---|---|---|
| Date & Time | Sep. 17 (Thu), 09:00-10:00 | ||
| Chair(s) |
Yoon Seok Choi (College of Medicine, The Catholic University of Korea, Korea) Meerim Park (National Cancer Center, Korea) |
||
| Speaker(s) | 09:00-09:10 | Discovery of a Novel Quiescence-Associated Marker of Top-Tier Hematopoietic Stem Cells in Umbilical Cord Blood by Transcriptomic Profiling Dong-Yeop Shin (Seoul National University College of Medicine, Korea) | |
| 09:10-09:20 | Ectopic EBV Infection in T Cells Identifies Reduced Therapeutic Responsiveness and Immune Dysfunction after Allogeneic Hematopoietic Stem Cell Transplantation Zhifan Zhao (Peking University, China) | ||
| 09:20-09:30 | An Integrated Single-Cell Atlas of Acute Lymphoblastic Leukemia Defines Malignant-Core State Architecture across Clinical and Molecular Contexts Javad Alizargar (National Taipei University of Nursing, Taiwan) | ||
| 09:30-09:40 | HLA Structural Profiles Identified by Protein Language Models Predict Graft Failure in Haploidentical Transplantation Rui Ma (Peking University People's Hospital, China) | ||
| 09:40-09:50 | Tumor Necrosis Factor is a Growth Factor for Mesenchymal Stromal Progenitor Cells Aleksei Bigildeev (Moscow Institute of Physics and Technology, Russia) | ||
| 09:50-10:00 | Optimization of Third–Party–derived Virus–Specific T Cell Manufacturing Using L-Arginine Supplementation and γδT Cell Restimulation Takahiro Tomoda (Institute of Science Tokyo, Japan) | ||
|
[OP04] Oral Presentation 4 |
Room D (2F) |
||
|---|---|---|---|
| Date & Time | Sep. 17 (Thu), 09:00-10:00 | ||
| Chair(s) |
Seong Hyun Jeong (Ajou University School of Medicine, Korea) Seok-Goo Cho (College of Medicine, The Catholic University of Korea, Korea) |
||
| Speaker(s) | 09:00-09:10 | Model-Predicted Antithymocyte Globulin Exposure and Clinical Outcomes after Haploidentical Peripheral Blood Stem Cell Transplantation in Adult Acute Myeloid Leukemia Daehun Kwag (College of Medicine, The Catholic University of Korea, Korea) | |
| 09:10-09:20 | Older Matched Sibling Donors Remain a Favorable Option in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia: Impact of Donor Age across Donor Types So Yeon Park (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:20-09:30 | Pegylated versus Daily G-CSF for Peripheral Blood Stem Cell Mobilization in Allogeneic Hematopoietic Cell Transplantation Donors Ryo Sato (Yamagata University, Japan) | ||
| 09:30-09:40 | Sequential Haploidentical-Cord Blood Hematopoietic Stem-Cell Transplantation with PT-Cy/Flu in Pediatric Acute Leukemia Zhilin Hu (Shenzhen Children's Hospital, China) | ||
| 09:40-09:50 | The Comparison of Bone Marrow plus Peripheral Blood versus Peripheral Blood as Graft Source in Haploidentical Stem Cell Transplantation for Older Patients Yi Liao (Peking University People's Hospital, China) | ||
| 09:50-10:00 | Successful Multi-Modal Management of Refractory CMV-Associated Hemophagocytic Lymphohistiocytosis and Idiopathic Pneumonia Syndrome Following HLA-Mismatched Bone Marrow Transplantation for Severe Aplastic Anemia Yuichi Kobayashi (Chiba University, Japan) | ||
|
Plenary Session 1 CAR T Cell Therapy Sep. 17 (Thu), 10:30-11:50 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) | |
Current Real World Practice to Optimize Outcomes of CAR T Cell Therapy for Pediatric ALL
Children's Hospital of Philadelphia, USA
A New Era of Sequential CAR‑T and Allogeneic HSCT
The First Affiliated Hospital, Zhejiang University School of Medicine, China
|
Luncheon Symposium 1 Sep. 17 (Thu), 12:00-12:40 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea) | |
Optimizing cGVHD Management After Ruxolitinib Failure: The Role of Belumosudil in Clinical Practice
The First Affiliated Hospital of Soochow University, China
|
Luncheon Symposium 2 Sep. 17 (Thu), 12:00-12:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea) | |
Maintaining Relative Dose Intensity in Elderly DLBCL: Clinical Strategies with Pegfilgrastim
Seoul National University Hospital, Korea
|
Luncheon Symposium 3 Sep. 17 (Thu), 12:00-12:40 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Deog-Yeon Jo (Chungnam National University College of Medicine, Korea) | |
Optimizing PNH Management with Iptacopan: Insights from Real-World Practice
College of Medicine, The Catholic University of Korea, Korea
|
Plenary Session 2 GVHD Sep. 17 (Thu), 13:00-14:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea) | |
Beyond Immunosuppression: Enhancing Tissue Tolerance to Mitigate GVHD through Nutritional Immunity
Dan L. Duncan Comprehensive Cancer Center, USA
Immunologic Mechanisms and Modulation of Chronic Graft-Versus-Host Disease (GVHD)
University of Minnesota, USA
|
Joint Symposium 1 (ASTCT-KSBMT) Evolving T-Cell Manipulation Strategies: Optimization of PTCy and New Frontiers in T-Cell Depletion Sep. 17 (Thu), 14:30-16:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Hyeon-Seok Eom (National Cancer Center, Korea) Margaret MacMillan (University of Minnesota, USA) |
|
Advances in Ex Vivo T Cell Depletion
University of Minnesota, USA
Selective T Cell Depletion and Enrichment
Fred Hutchinson Cancer Center, USA
Optimizing T-Cell Modulation in Adult ALL Transplantation ; ATG, PTCy, and Donor-Specific GVHD Control
College of Medicine, The Catholic University of Korea, Korea
|
Scientific Session 1 Next-Generation Immune Effector Cell Therapies: Emerging Platforms and Biological Insights Sep. 17 (Thu), 14:30-16:00 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea) Deok Hwan Yang (Chonnam National University Medical School, Korea) |
|
Spatially Confined IL-12 Programs CAR-NK through mTORC1 to Coordinate Antitumor Immune Networks
Dana-Farber Cancer Institute, USA
In Vivo CAR-T Therapy: A Paradigm Shift Toward Ready-to-Use Cancer Immunotherapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Overcoming Resistance in T-Cell Malignancies: From Phase 1 Study of CD5-Targeted Allogeneic CAR-NK Cells
University of Ulsan College of Medicine, Korea
|
Scientific Session 2 Advances in Immunotherapy and Transplant Strategies in Pediatric Hematologic Malignancies Sep. 17 (Thu), 14:30-16:00 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea) Jun Eun Park (Korea University College of Medicine, Korea) |
|
Virus-Specific T Cells for Adoptive Immunotherapy
Dana-Farber Cancer Institute, USA
Strategies for Determining Treatment Flow of CAR T-Cell Therapy and HSCT in Pediatric ALL
Wroclaw Medical University, Poland
Clinical Applications of Donor Lymphocyte Infusion in Pediatric Malignancies
Sungkyunkwan University School of Medicine, Korea
|
Education Session 1 Additional Cellular Support after Allogeneic Transplantation Sep. 17 (Thu), 14:30-16:00 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Yeung-Chul Mun (Ewha Womans University College of Medicine, Korea) Hyoung Soo Choi (Seoul National University College of Medicine, Korea) |
|
Management of Poor Graft Function in Children
Korea University College of Medicine, Korea
Donor Lymphocyte Infusion (DLI) in 2026: Indications, Dosing, and GVHD Trade-offs
University of Ulsan College of Medicine, Korea
Cellular Support Beyond the Graft – The Continuing Promise of Umbilical Cord Blood Grafts
Case Western Reserve University School of Medicine, USA
|
Joint Symposium 2 (EBMT-KSBMT) Evolving Donor Issues in Allogeneic HSCT: From HLA Matching to Germline Screening and Emerging Concerns Sep. 17 (Thu), 16:50-18:30 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) Ibrahim Yakoub-Agha (Lille University Hospital, France) |
|
Germline Traits and Donor Selection for Allo-HCT: on Overview and the Paradigm of DDX41
University of Tor Vergata, Italy
Which Donor Should We Use in the Absence of a Matched Sibling in Aplastic Anemia?
La Fe University and Polytechnic Hospital, Spain
Clonal Hematopoiesis in Hematopoietic Stem Cell Transplantation
Seoul National University College of Medicine, Korea
Hematopoietic Stem Cell Donor Selection in 2026: Evolving Perspectives and Current Challenges
University of Ulsan College of Medicine, Korea
|
Scientific Session 3 Post-Transplant Residual Disease in Acute Leukemia: Monitoring and Therapeutic Strategies Sep. 17 (Thu), 16:50-18:20 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Myungshin Kim (The Catholic University of Korea, Korea) Ho-Jin Shin (Pusan National University School of Medicine, Korea) |
|
Flow Cytometric MRD for AML: Updates in 2026
Amsterdam UMC, The Netherlands
Targeting Residual Disease after Transplant: The Convergence of HCT and Engineered Cellular Therapies
Columbia University Medical Center, USA
Clinical Experience with NGS-based Chimerism Analyses in HSCT Patients
Yonsei University College of Medicine, Korea
|
Scientific Session 4 Science Behind Treatment Response and Relapse Sep. 17 (Thu), 16:50-18:20 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Won-Sik Lee (Inje University College of Medicine, Korea) Sung-Soo Yoon (Kyung Hee University College of Medicine, Korea) |
|
Longitudinal Single-Cell Dissection of Venetoclax Resistance in Secondary AML
UNIST, Korea
Improving Post-Transplant Immunological Outcome in AML by Modulating VISTA
Vanderbilt University Medical Center, USA
Immune Escape as a Mechanism of Post-Transplant Relapse
Taussig Cancer Institute, USA
